GlassScriptPhysician profile
Sohaib Jamil
NPI 1417215161
$6,933.31
in general payments reported to CMS, 2019-2025
34 companies · $1,827 in 2025
The $1,827 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $272 · 2021: $260 · 2022: $877 · 2023: $1,879 · 2024: $1,393 · 2025: $1,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,998 · Honoraria: $1,000 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,998.03 |
| Honoraria | $1,000.00 |
| Education | $101.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,431.69 | 2019-2025 | |
| Erbe USA INC | $1,080.00 | 2019-2023 | |
| Janssen Biotech, INC. | $929.94 | 2019-2025 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $681.61 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $451.40 | 2019-2024 | Exalt Model D |
| Takeda Pharmaceuticals U.S.A., INC. | $387.61 | 2019-2025 | Entyvio |
| Pfizer INC. | $215.52 | 2021-2025 | |
| Qol Medical, LLC | $190.91 | 2024-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.05 | 2019-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $146.34 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $130.94 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $130.22 | 2022-2025 | Dupixent |
| Fujifilm Healthcare Americas Corporation | $119.39 | 2025 | |
| Medtronic, INC. | $104.85 | 2025 | Barrx |
| Madrigal Pharmaceuticals | $96.52 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $90.73 | 2024-2025 | Omvoh |
| Endogastric Solutions, INC | $81.67 | 2022 | |
| Ardelyx, INC. | $69.93 | 2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $56.86 | 2023 | |
| Amgen INC. | $39.15 | 2022-2023 | Avsola, Amjevita |
| Alfasigma USA, INC. | $30.96 | 2020 | |
| Allergan, INC. | $30.19 | 2019 | |
| Ucb, INC. | $28.59 | 2019-2020 | |
| Genzyme Corporation | $24.80 | 2025 | |
| Intercept Pharmaceuticals, INC. | $24.51 | 2025 | |
| Aimmune Therapeutics, INC. | $24.42 | 2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.10 | 2023 | Cyltezo |
| Shire North American Group INC | $22.86 | 2019 | |
| Novo Nordisk INC | $21.53 | 2025 | Wegovy |
| Exact Sciences Corporation | $19.82 | 2024 | Cologuard Collection Kit |
| Braintree Laboratories, INC. | $18.93 | 2019 | |
| Merck Sharp & Dohme LLC | $18.10 | 2019 | |
| Celltrion USA INC. | $17.80 | 2024 | Zymfentra |
| Ferring Pharmaceuticals INC. | $16.37 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohaib Jamil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.